We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. Schematic representation of metabolic pathways of endocannabinoids. From: Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Abbreviations: 2-AG, 2-arachidonoylglycerol; 2LNArPE, 2-l-N-arachidonoyl-phosphatidylethanolamine; AA, arachidonic acid; ABH, A-CoA, arachidonoyl-CoA; αβ-hydrolases; AEA, anandamide; COX2, cyclooxygenase 2; DAGLs, sn-1-selective diacylglycerol lipases; FAAH, fatty acid amide hydrolase; GDE1, glycerophosphodiester phosphodiesterase 1; GPAEA, Glycerophosphoanandamide; MAGL, monoacylglycerol lipase; NAPE-PLD, N-acyl-phosphatidylethanolamine-selective phosphodiesterase; NATs, N-acyltransferases; NArPE, N-arachidonoyl-phosphatidylethanolamine; PA, Phosphatidic acid; PE, Phosphatidylethanolamine; PGE2-G, Prostaglandin E2 glycerol ester; PMF2a, Prostamide F2a; (s)PLA1/2, (soluble) phospholipase A1/2; PLC, phospholipase C; PLCβ, phospholipase Cβ; PLD, phospholipase D;PTPN22, protein tyrosine phosphatase, non-receptor type 22; S1LPL, sn-1-lysophospholipid; S2AA, sn-2-arachidonic acid; S2LPA, sn-2-lysophosphatidic acid.

Atsushi Saito, et al. Neurobiol Dis. 2013 May;53:10-17.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk